Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies

Cited 217 time in webofscience Cited 0 time in scopus
  • Hit : 517
  • Download : 0
DC FieldValueLanguage
dc.contributor.authorRodgers, David T.ko
dc.contributor.authorMazagova, Magdalenako
dc.contributor.authorHampton, Eric N.ko
dc.contributor.authorCao, Yuko
dc.contributor.authorRamadoss, Nitya S.ko
dc.contributor.authorHardy, Ian R.ko
dc.contributor.authorSchulman, Andrewko
dc.contributor.authorDu, Juanjuanko
dc.contributor.authorWang, Fengko
dc.contributor.authorSinger, Odedko
dc.contributor.authorMa, Jenniferko
dc.contributor.authorNunez, Vanessako
dc.contributor.authorShen, Jiayinko
dc.contributor.authorWoods, Ashley K.ko
dc.contributor.authorWright, Timothy M.ko
dc.contributor.authorSchultz, Peter G.ko
dc.contributor.authorKim, Chan Hyukko
dc.contributor.authorYoung, Travis S.ko
dc.date.accessioned2016-07-04T06:01:10Z-
dc.date.available2016-07-04T06:01:10Z-
dc.date.created2016-05-14-
dc.date.created2016-05-14-
dc.date.issued2016-01-
dc.identifier.citationPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, v.113, no.4, pp.459 - 468-
dc.identifier.issn0027-8424-
dc.identifier.urihttp://hdl.handle.net/10203/209118-
dc.description.abstractChimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in clinical trials for B-cell malignancies. However, safety concerns related to the inability to control CAR-T cells once infused into the patient remain a significant challenge. Here we report the engineering of recombinant antibody-based bifunctional switches that consist of a tumor antigen-specific Fab molecule engrafted with a peptide neo-epitope, which is bound exclusively by a peptide-specific switchable CAR-T cell (sCAR-T). The switch redirects the activity of the bio-orthogonal sCAR-T cells through the selective formation of immunological synapses, in which the sCAR-T cell, switch, and target cell interact in a structurally defined and temporally controlled manner. Optimized switches specific for CD19 controlled the activity, tissue-homing, cytokine release, and phenotype of sCAR-T cells in a dose-titratable manner in a Nalm-6 xenograft rodent model of B-cell leukemia. The sCAR-T-cell dosing regimen could be tuned to provide efficacy comparable to the corresponding conventional CART-19, but with lower cytokine levels, thereby offering a method of mitigating cytokine release syndrome in clinical translation. Furthermore, we demonstrate that this methodology is readily adaptable to targeting CD20 on cancer cells using the same sCAR-T cell, suggesting that this approach may be broadly applicable to heterogeneous and resistant tumor populations, as well as other liquid and solid tumor antigens.-
dc.languageEnglish-
dc.publisherNATL ACAD SCIENCES-
dc.subjectCHIMERIC ANTIGEN RECEPTOR-
dc.subjectACUTE LYMPHOBLASTIC-LEUKEMIA-
dc.subjectADOPTIVE IMMUNOTHERAPY-
dc.subjectCANCER-IMMUNOTHERAPY-
dc.subjectMONOCLONAL-ANTIBODY-
dc.subjectADVERSE EVENT-
dc.subjectSAFETY SWITCH-
dc.subjectIN-VITRO-
dc.subjectTHERAPY-
dc.subjectDESIGN-
dc.titleSwitch-mediated activation and retargeting of CAR-T cells for B-cell malignancies-
dc.typeArticle-
dc.identifier.wosid000368617900010-
dc.identifier.scopusid2-s2.0-84955503891-
dc.type.rimsART-
dc.citation.volume113-
dc.citation.issue4-
dc.citation.beginningpage459-
dc.citation.endingpage468-
dc.citation.publicationnamePROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-
dc.identifier.doi10.1073/pnas.1524155113-
dc.contributor.localauthorKim, Chan Hyuk-
dc.contributor.nonIdAuthorRodgers, David T.-
dc.contributor.nonIdAuthorMazagova, Magdalena-
dc.contributor.nonIdAuthorHampton, Eric N.-
dc.contributor.nonIdAuthorCao, Yu-
dc.contributor.nonIdAuthorRamadoss, Nitya S.-
dc.contributor.nonIdAuthorHardy, Ian R.-
dc.contributor.nonIdAuthorSchulman, Andrew-
dc.contributor.nonIdAuthorDu, Juanjuan-
dc.contributor.nonIdAuthorWang, Feng-
dc.contributor.nonIdAuthorSinger, Oded-
dc.contributor.nonIdAuthorMa, Jennifer-
dc.contributor.nonIdAuthorNunez, Vanessa-
dc.contributor.nonIdAuthorShen, Jiayin-
dc.contributor.nonIdAuthorWoods, Ashley K.-
dc.contributor.nonIdAuthorWright, Timothy M.-
dc.contributor.nonIdAuthorSchultz, Peter G.-
dc.contributor.nonIdAuthorYoung, Travis S.-
dc.type.journalArticleArticle-
dc.subject.keywordAuthorchimeric antigen receptor T cell-
dc.subject.keywordAuthorautologous cell therapy-
dc.subject.keywordAuthorantibody engineering-
dc.subject.keywordAuthorcancer-
dc.subject.keywordAuthorleukemia-
dc.subject.keywordPlusCHIMERIC ANTIGEN RECEPTOR-
dc.subject.keywordPlusACUTE LYMPHOBLASTIC-LEUKEMIA-
dc.subject.keywordPlusADOPTIVE IMMUNOTHERAPY-
dc.subject.keywordPlusCANCER-IMMUNOTHERAPY-
dc.subject.keywordPlusMONOCLONAL-ANTIBODY-
dc.subject.keywordPlusADVERSE EVENT-
dc.subject.keywordPlusSAFETY SWITCH-
dc.subject.keywordPlusIN-VITRO-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusDESIGN-
Appears in Collection
BS-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 217 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0